GALLIPRANT DIN 02484277
Status: Marketed
Holder: ELANCO CANADA LIMITED
Health Canada record
| Active ingredient(s) | GRAPIPRANT 100 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 12-Jun-2019 |
|---|
| Current status date | 12-Jun-2019 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Elanco Canada Limited — licence 102236, currently licensed, last inspection rating C (2022-08-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GRAPIPRANT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02484250 | GALLIPRANT | ELANCO CANADA LIMITED | Tablet | GRAPIPRANT 20 MG | Marketed |
| 02484269 | GALLIPRANT | ELANCO CANADA LIMITED | Tablet | GRAPIPRANT 60 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 21707 | 2019-01-08 | New Drug Submission (NDS) | |
Request a quote for GALLIPRANT
How to read a Canadian DIN record